SCHEMBL2431686

SCHEMBL2431686

CC(Cc1ccc(OCc2ccc(C(F)(F)F)c3c2OC(C)(C)C3)cc1)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.40
FFAR1 O14842 2/20 0.39
PPARG P37231 2/20 0.39
EPHX2 P34913 1/20 0.39
MME P08473 3/20 0.38
ACE P12821 3/20 0.38
CPA1 P15085 3/20 0.38
ACE2 Q9BYF1 3/20 0.38
FFAR4 Q5NUL3 3/20 0.38
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
PPARD Q03181 3/20 0.37
PPARA Q07869 3/20 0.37
S1PR1 P21453 1/20 0.36
ITGA4 P13612 1/20 0.36
KMT2A Q03164 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
ADAMTS4 O75173 1/20 0.35
MMP13 P45452 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2434217 0.88 FFAR4 (0.52) FFAR1PPARGEPHX2FFAR4KMT2A
SCHEMBL2433983 0.87 MME (0.41) FFAR1PPARGMMEACECPA1
SCHEMBL2436884 0.87 FFAR4 (0.41) FFAR1PPARGEPHX2FFAR4PPARD
SCHEMBL2434080 0.83 FFAR1 (0.43) FFAR1PPARGMMEACECPA1
SCHEMBL2436946 0.80 KDM5A (0.48) FFAR1ITGA4KMT2A
SCHEMBL9983534 0.79 PTGER4 (0.41) FFAR1PPARGMMEACECPA1
SCHEMBL9983481 0.79 PTGER4 (0.41) FFAR1PPARGMMEACECPA1
SCHEMBL2432014 0.79 PTGER4 (0.41) FFAR1PPARGMMEACECPA1
SCHEMBL3000273 0.79 GYS1 (0.44) FFAR1PPARGMMEACECPA1
SCHEMBL2432792 0.79 GYS1 (0.44) FFAR1PPARGMMEACECPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2582674-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2013-04-24 EP claimed
EP-2367793-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX INC (US) 2013-03-27 EP claimed
US-8309600-B2 GPR120 receptor agonists and uses thereof METABOLEX INC. (US) 2012-11-13 US claimed
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2011-12-22 US claimed
WO-2011159297-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2011-12-22 WO claimed
EP-2367793-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2011-09-28 EP claimed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US claimed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 WO claimed
EP-2582674-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF CYMABAY THERAPEUTICS INC (US) 2014-10-01 EP disclosed
EP-2582674-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF CYMABAY THERAPEUTICS INC (US) 2014-10-01 EP disclosed
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2014-05-01 US disclosed
US-8598374-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-12-03 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
EP-2367793-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2011-09-28 EP disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 WO disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR NR1H4 118/4885FFAR1 22/4885PPARG 39/4885
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR NR1H4 118/4885FFAR1 22/4885PPARG 39/4885
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR NR1H4 118/4885FFAR1 22/4885PPARG 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.